抗精神病药诱导的高催乳素血症的治疗:多巴胺能受体D2部分激动剂阿立哌唑作用的最新进展。

Domenico De Berardis, Michele Fornaro, Nicola Serroni, Stefano Marini, Monica Piersanti, Marilde Cavuto, Alessandro Valchera, Monica Mazza, Gabriella Girinelli, Felice Iasevoli, Giampaolo Perna, Giovanni Martinotti, Massimo Di Giannantonio
{"title":"抗精神病药诱导的高催乳素血症的治疗:多巴胺能受体D2部分激动剂阿立哌唑作用的最新进展。","authors":"Domenico De Berardis,&nbsp;Michele Fornaro,&nbsp;Nicola Serroni,&nbsp;Stefano Marini,&nbsp;Monica Piersanti,&nbsp;Marilde Cavuto,&nbsp;Alessandro Valchera,&nbsp;Monica Mazza,&nbsp;Gabriella Girinelli,&nbsp;Felice Iasevoli,&nbsp;Giampaolo Perna,&nbsp;Giovanni Martinotti,&nbsp;Massimo Di Giannantonio","doi":"10.2174/1872214807666131229125700","DOIUrl":null,"url":null,"abstract":"<p><p>Hyperprolactinemia is an unwanted adverse effect present in several typical and atypical antipsychotics. Aripiprazole is a drug with partial agonist activity at the level of dopamine receptors D2, which may be effective for antipsychotic- induced hyperprolactinemia. Therefore, we analyzed the literature concerning the treatment of antipsychoticinduced hyperprolactinemia with aripiprazole by updating a previous paper written on the same topic. More recent studies were reviewed. They showed that there are two options for the treatment of antipsychotic-induced hyperprolactinemia with aripiprazole. The safest strategy may require the addition of aripiprazole to ongoing treatments, in the case patients had previously responded to antipsychotic drugs and then developed hyperprolactinemia. However, it is advisable to monitor the patients in case relapses and/or side effect, although rare, might occur. Switching drugs should be considered when a patient does not appear to be responding to the previous antipsychotic, thus developing hyperprolactinemia. A cross-taper switch should always be considered, but the risk of a relapse in the disorder may occur more frequently and the patients should be closely monitored. However, limitations must be considered and further studies are needed to definitely elucidate this important issue. Some relevant patents are also described in this review. </p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 1","pages":"30-7"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214807666131229125700","citationCount":"24","resultStr":"{\"title\":\"Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.\",\"authors\":\"Domenico De Berardis,&nbsp;Michele Fornaro,&nbsp;Nicola Serroni,&nbsp;Stefano Marini,&nbsp;Monica Piersanti,&nbsp;Marilde Cavuto,&nbsp;Alessandro Valchera,&nbsp;Monica Mazza,&nbsp;Gabriella Girinelli,&nbsp;Felice Iasevoli,&nbsp;Giampaolo Perna,&nbsp;Giovanni Martinotti,&nbsp;Massimo Di Giannantonio\",\"doi\":\"10.2174/1872214807666131229125700\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hyperprolactinemia is an unwanted adverse effect present in several typical and atypical antipsychotics. Aripiprazole is a drug with partial agonist activity at the level of dopamine receptors D2, which may be effective for antipsychotic- induced hyperprolactinemia. Therefore, we analyzed the literature concerning the treatment of antipsychoticinduced hyperprolactinemia with aripiprazole by updating a previous paper written on the same topic. More recent studies were reviewed. They showed that there are two options for the treatment of antipsychotic-induced hyperprolactinemia with aripiprazole. The safest strategy may require the addition of aripiprazole to ongoing treatments, in the case patients had previously responded to antipsychotic drugs and then developed hyperprolactinemia. However, it is advisable to monitor the patients in case relapses and/or side effect, although rare, might occur. Switching drugs should be considered when a patient does not appear to be responding to the previous antipsychotic, thus developing hyperprolactinemia. A cross-taper switch should always be considered, but the risk of a relapse in the disorder may occur more frequently and the patients should be closely monitored. However, limitations must be considered and further studies are needed to definitely elucidate this important issue. Some relevant patents are also described in this review. </p>\",\"PeriodicalId\":89474,\"journal\":{\"name\":\"Recent patents on endocrine, metabolic & immune drug discovery\",\"volume\":\"8 1\",\"pages\":\"30-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2174/1872214807666131229125700\",\"citationCount\":\"24\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent patents on endocrine, metabolic & immune drug discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1872214807666131229125700\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on endocrine, metabolic & immune drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872214807666131229125700","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 24

摘要

高泌乳素血症是存在于几种典型和非典型抗精神病药物的不良反应。阿立哌唑是一种在多巴胺受体D2水平上具有部分激动剂活性的药物,可能对抗精神病性高催乳素血症有效。因此,我们对有关阿立哌唑治疗抗精神病性高泌乳素血症的文献进行了分析,并更新了先前的一篇相同主题的论文。对最近的研究进行了回顾。他们表明,阿立哌唑治疗抗精神病药物引起的高泌乳素血症有两种选择。最安全的策略可能需要在正在进行的治疗中添加阿立哌唑,如果患者先前对抗精神病药物有反应,然后出现高泌乳素血症。然而,建议监测患者,以防复发和/或副作用,虽然罕见,但可能发生。当患者对先前的抗精神病药物似乎没有反应,从而出现高泌乳素血症时,应考虑转换药物。应始终考虑交叉锥形开关,但疾病复发的风险可能会更频繁地发生,患者应密切监测。然而,必须考虑到局限性,需要进一步的研究来明确阐明这一重要问题。本文还介绍了一些相关专利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.

Hyperprolactinemia is an unwanted adverse effect present in several typical and atypical antipsychotics. Aripiprazole is a drug with partial agonist activity at the level of dopamine receptors D2, which may be effective for antipsychotic- induced hyperprolactinemia. Therefore, we analyzed the literature concerning the treatment of antipsychoticinduced hyperprolactinemia with aripiprazole by updating a previous paper written on the same topic. More recent studies were reviewed. They showed that there are two options for the treatment of antipsychotic-induced hyperprolactinemia with aripiprazole. The safest strategy may require the addition of aripiprazole to ongoing treatments, in the case patients had previously responded to antipsychotic drugs and then developed hyperprolactinemia. However, it is advisable to monitor the patients in case relapses and/or side effect, although rare, might occur. Switching drugs should be considered when a patient does not appear to be responding to the previous antipsychotic, thus developing hyperprolactinemia. A cross-taper switch should always be considered, but the risk of a relapse in the disorder may occur more frequently and the patients should be closely monitored. However, limitations must be considered and further studies are needed to definitely elucidate this important issue. Some relevant patents are also described in this review.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信